HC Wainwright Lowers LAVA Therapeutics (NASDAQ:LVTX) Price Target to $2.00

LAVA Therapeutics (NASDAQ:LVTX) had its target price lowered by HC Wainwright from $6.00 to $2.00 in a research report report published on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other research firms also recently issued reports on LVTX. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Leerink Partnrs downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. Leerink Partners reiterated a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. Finally, JMP Securities restated a “market perform” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $3.33.

LAVA Therapeutics Trading Up 4.2 %

Shares of LVTX stock opened at $1.03 on Friday. The firm’s 50 day moving average is $1.62 and its 200 day moving average is $1.78. The stock has a market capitalization of $26.11 million, a P/E ratio of -1.00 and a beta of 0.43. LAVA Therapeutics has a 12 month low of $0.96 and a 12 month high of $6.47.

Hedge Funds Weigh In On LAVA Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pathway Financial Advisors LLC raised its holdings in shares of LAVA Therapeutics by 70.8% in the 3rd quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock valued at $170,000 after acquiring an additional 42,500 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of LAVA Therapeutics during the 2nd quarter valued at $55,000. Finally, Virtu Financial LLC bought a new stake in shares of LAVA Therapeutics during the 3rd quarter worth $32,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.